Clinical Trial

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-09-26; most recent amendment 2025-10-24.
Status change: Not Yet Recruiting → Recruiting 2025-02-07
Trial Details
NCT Number NCT06617923
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: National Cancer Institute (NCI), Impact Therapeutics
Conditions Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Enrollment 18 participants
Start Date 2025-02-06
Primary Completion 2027-10 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-27